4th Gene Therapy Comparability Summit 2024

Conference themes
The late-stage gene therapy pipeline is rapidly evolving, with 10+ approvals across the FDA and EMA in the past year and several more BLA filings and decisions expected by the beginning of 2024.

As momentum builds towards significantly higher numbers of active later-stage clinical trials, the importance drug developers and regulators are placing on comparability is increasing too.

Professional congress organizer (PCO)
Hanson Wade

Notes
Brochure: https://go.evvnt.com/2017303-3?pid=4832

Speakers: Anubhav Arora, Director - Chemistry, Manufacturing and Controls, Apellis Pharmaceuticals, and more

https://go.evvnt.com/2017303-2?pid=4832

Ms. Anita Kelemen